Overview

A Phase IV Study to Assess the Impact of the Change of Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With HIV Infection

Status:
Recruiting

Trial end date:
2022-09-15

Target enrollment:

Participant gender:

Summary

242 patients (121 patients in each of the two treatment arms) will be included with a confirmed diagnosis of HIV-1 infection and with a stable antiretroviral treatment during more than 48 weeks with dual therapy (DTG + 3TC)

Phase:

Phase 4

Details

Lead Sponsor:

Fundacion SEIMC-GESIDA

Treatments:

Anti-Retroviral Agents